PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPembrolizumab
Keytruda(pembrolizumab)
Keytruda (pembrolizumab) is an antibody pharmaceutical. Pembrolizumab was first approved as Keytruda on 2014-09-04. It is used to treat hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat endometrial neoplasms, hodgkin disease, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
COVID-19
Drugs Approved for Childhood Cancers
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
genetic phenomenaD055614
Trade Name
FDA
EMA
Keytruda (discontinued: Keytruda)
Combinations
Keytruda qlex
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pembrolizumab
Tradename
Proper name
Company
Number
Date
Products
KeytrudapembrolizumabMerck & CoN-125514 RX2015-01-15
1 products
Show 1 discontinued
Berahyaluronidase alfa
+
Pembrolizumab
Tradename
Proper name
Company
Number
Date
Products
Keytruda Qlexpembrolizumab and berahyaluronidase alfa-pmphMerck & CoN-761467 RX2025-09-19
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
keytrudaBiologic Licensing Application2025-08-19
keytruda qlexBiologic Licensing Application2025-11-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
renal cell carcinomaEFO_0000376D002292—
non-small-cell lung carcinoma—D002289—
triple negative breast neoplasms—D064726—
hepatocellular carcinoma—D006528C22.0
urinary bladder neoplasms—D001749C67
hodgkin disease—D006689C81
melanoma—D008545—
urethral neoplasmsEFO_0003846D014523—
transitional cell carcinoma—D002295—
ureteral neoplasmsEFO_0003844D014516C66
Show 3 more
Agency Specific
FDA
EMA
Expiration
Code
pembrolizumab, Keytruda, Merck Sharp & Dohme LLC
2028-12-03Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF02: Pembrolizumab
HCPCS
Code
Description
J9271
Injection, pembrolizumab, 1 mg
Clinical
Clinical Trials
2747 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——258296115349601
NeoplasmsD009369—C8038623113219503
CarcinomaD002277—C80.013623337121366
MelanomaD008545——17719128136353
Squamous cell carcinoma of head and neckD000077195——12216426111267
Breast neoplasmsD001943EFO_0003869C5010315016111237
Triple negative breast neoplasmsD064726——861141315185
Renal cell carcinomaD002292EFO_0000376—83831316149
AdenocarcinomaD000230——4183421115
Pancreatic neoplasmsD010190EFO_0003860C25635311297
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175—C34.9012615944—34299
Squamous cell carcinomaD002294——7111817—7180
Colorectal neoplasmsD015179——107918—10174
Neoplasm metastasisD009362EFO_0009708—807214—5134
Head and neck neoplasmsD006258——538015—5122
Stomach neoplasmsD013274EFO_0003897C16596812—3113
Ovarian neoplasmsD010051EFO_0003893C5661704—2109
Hepatocellular carcinomaD006528—C22.039529—19100
Liver neoplasmsD008113EFO_1001513C22.0385110—1496
RecurrenceD012008——31724—492
Show 75 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228—C85.92222———34
B-cell lymphomaD016393——1720——133
Large b-cell lymphoma diffuseD016403—C83.31620———30
Castration-resistant prostatic neoplasmsD064129——1213———23
Pancreatic ductal carcinomaD021441——1315———21
Microsatellite instabilityD053842——1113———20
T-cell lymphomaD016399——917———20
Follicular lymphomaD008224—C821213———20
LeukemiaD007938—C9598——117
Myeloid leukemia acuteD015470—C92.099———16
Show 193 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Endocrine system diseasesD004700EFO_0001379E34.91———12
NeuroblastomaD009447EFO_0000621—2————2
RhabdomyosarcomaD012208——2————2
Bites and stingsD001733——2————2
Liver diseasesD008107EFO_0001421K70-K771———12
MedulloblastomaD008527——2————2
Motor activityD009043EFO_0003940—1———12
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1————1
Myelomonocytic leukemia chronicD015477—C93.11————1
AnemiaD000740EFO_0004272D64.91————1
Show 43 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MyocarditisD009205—I51.4————33
Autoimmune diseasesD001327EFO_0000540M30-M36————33
Interstitial lung diseasesD017563EFO_0004244J84.9————33
Heart diseasesD006331EFO_0003777I51.9————22
Human influenzaD007251EFO_0007328J11.1————22
Cardiovascular diseasesD002318EFO_0000319I98————11
CardiomyopathiesD009202EFO_0000318I42————11
PericarditisD010493EFO_0007427I30————11
VasculitisD014657EFO_0006803M31————11
MyositisD009220EFO_0000783G72.49————11
Show 22 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePembrolizumab
INNpembrolizumab
Description
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>5GGS:A,C|heavy chain QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAY MELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH >5GGS:B,D|light chain EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5B8C, 5DK3, 5GGS, 5JXE
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL3137343
ChEBI ID—
PubChem CID—
DrugBankDB09037
UNII IDDPT0O3T46P (ChemIDplus, GSRS)
Target
Agency Approved
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Keytruda – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 81,956 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
77,251 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use